Abstract：
The goal of this survey was to evaluate the treatment and practice pattern of patients with high-grade papillary Ta, T1 nonmuscle-invasive bladder cancer (NMIBC), and carcinoma in situ (CIS) in bacillus Calmette-Guérin (BCG)-unresponsive (with adequate BCG exposure = adequate BCG) and those with less than adequate BCG exposure (BCG-exposed).
An internet-based survey with a target duration of 5 minutes was sent to US urologists who manage patients with NMIBC. Respondents were recruited from the Sesen Bio target list based upon BCG utilization.
In 2022, 100 urologists who manage patients with papillary tumors and 159 urologists who manage patients with CIS tumors filled out the survey. Most (78%) were community-based urologists. Study respondents managed an average of 33 (range: 6-158) CIS patients and 44 (range: 10-200) high-grade patients with papillary disease (without CIS) over the past 6 months. Approximately 70% of physicians identified either gemcitabine (∼40%) or mitomycin C (∼30%) as the most often used intravesical chemotherapies for BCG unresponsive and BCG exposed groups. Most physicians reported the use of gemcitabine 2 g or mitomycin C 40 mg in a specific regimen for induction (once a week × 6 weeks) and maintenance (once a month × 12 months). Responses were consistent across groups of BCG therapy (adequate vs BCG-exposed). Physicians were slightly more likely to use a maintenance regimen for the adequate BCG patient.
The most common treatments received by patients with BCG-unresponsive and BCG-exposed NMIBC were intravesical chemotherapy (single-agent gemcitabine or mitomycin C), regardless of whether CIS or papillary disease was present.
An internet-based survey with a target duration of 5 minutes was sent to US urologists who manage patients with NMIBC. Respondents were recruited from the Sesen Bio target list based upon BCG utilization.
In 2022, 100 urologists who manage patients with papillary tumors and 159 urologists who manage patients with CIS tumors filled out the survey. Most (78%) were community-based urologists. Study respondents managed an average of 33 (range: 6-158) CIS patients and 44 (range: 10-200) high-grade patients with papillary disease (without CIS) over the past 6 months. Approximately 70% of physicians identified either gemcitabine (∼40%) or mitomycin C (∼30%) as the most often used intravesical chemotherapies for BCG unresponsive and BCG exposed groups. Most physicians reported the use of gemcitabine 2 g or mitomycin C 40 mg in a specific regimen for induction (once a week × 6 weeks) and maintenance (once a month × 12 months). Responses were consistent across groups of BCG therapy (adequate vs BCG-exposed). Physicians were slightly more likely to use a maintenance regimen for the adequate BCG patient.
The most common treatments received by patients with BCG-unresponsive and BCG-exposed NMIBC were intravesical chemotherapy (single-agent gemcitabine or mitomycin C), regardless of whether CIS or papillary disease was present.
摘要：
背景：这项调查的目的是评估高度乳头状Ta患者的治疗和实践模式，T1非肌层浸润性膀胱癌（NMIBC），卡介苗（BCG）的原位癌（CIS）-无反应（具有足够的BCG暴露=足够的BCG）和BCG暴露不足（BCG暴露）的原位癌。
方法：向管理NMIBC患者的美国泌尿科医师发送了一项基于互联网的调查，目标持续时间为5分钟。根据BCG的使用情况，从塞森生物目标列表中招募受访者。
结果：2022年，100名处理乳头状肿瘤患者的泌尿科医师和159名处理CIS肿瘤患者的泌尿科医师完成了调查。大多数（78％）是社区泌尿科医师。在过去的6个月中，研究受访者平均管理33例（范围：6-158）CIS患者和44例（范围：10-200）高度乳头状疾病（不包括CIS）患者。大约70％的医生认为吉西他滨（〜40％）或丝裂霉素C（〜30％）是BCG无反应和BCG暴露组最常用的膀胱内化疗。大多数医生报告在特定方案中使用吉西他滨2g或丝裂霉素C40mg进行诱导（每周×6周）和维持（每月×12个月）。BCG治疗组之间的反应是一致的（足够的vsBCG暴露）。医生更有可能对足够的BCG患者使用维持方案。
结论：BCG无反应且暴露于BCG的NMIBC患者接受的最常见治疗是膀胱内化疗（单药吉西他滨或丝裂霉素C），无论是否存在CIS或乳头状疾病。
方法：向管理NMIBC患者的美国泌尿科医师发送了一项基于互联网的调查，目标持续时间为5分钟。根据BCG的使用情况，从塞森生物目标列表中招募受访者。
结果：2022年，100名处理乳头状肿瘤患者的泌尿科医师和159名处理CIS肿瘤患者的泌尿科医师完成了调查。大多数（78％）是社区泌尿科医师。在过去的6个月中，研究受访者平均管理33例（范围：6-158）CIS患者和44例（范围：10-200）高度乳头状疾病（不包括CIS）患者。大约70％的医生认为吉西他滨（〜40％）或丝裂霉素C（〜30％）是BCG无反应和BCG暴露组最常用的膀胱内化疗。大多数医生报告在特定方案中使用吉西他滨2g或丝裂霉素C40mg进行诱导（每周×6周）和维持（每月×12个月）。BCG治疗组之间的反应是一致的（足够的vsBCG暴露）。医生更有可能对足够的BCG患者使用维持方案。
结论：BCG无反应且暴露于BCG的NMIBC患者接受的最常见治疗是膀胱内化疗（单药吉西他滨或丝裂霉素C），无论是否存在CIS或乳头状疾病。
